Back to Browse Journals » Journal of Blood Medicine » Volume 1

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia

Authors Lisa M Lima, Martha Arellano, Stacie Holloway, et al

Published Date September 2010 Volume 2010:1 Pages 221—225

DOI http://dx.doi.org/10.2147/JBM.S7158

Published 10 September 2010

Lisa M Lima, Martha Arellano, Stacie Holloway, Marian Shepard, Stephanie McMillan, Hanna Jean Khoury
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

Abstract: Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.

Keywords: dasatinib, resistant CML, outcomes

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008

Problems and barriers of pain management in the emergency department: Are we ever going to get better?

Sergey M Motov, Abu NGA Khan

Journal of Pain Research 2009, 2:5-11

Published Date: 9 December 2008

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies

Jorge Castillo, Kimberly Perez

Journal of Blood Medicine 2010, 1:1-8

Published Date: 25 February 2010

Treatment of hemophilia: a review of current advances and ongoing issues

Antonio Coppola, Mirko Di Capua, Matteo Nicola Dario, et al.

Journal of Blood Medicine 2010, 1:183-195

Published Date: 30 August 2010

Facial transplantation: a review of ethics, progress, and future targets

Edwards JA, Mathes DW

Transplant Research and Risk Management 2011, 3:113-125

Published Date: 5 September 2011

Treatments for chronic myeloid leukemia: a qualitative systematic review

Ferdinand R, Mitchell SA, Batson S, Tumur I

Journal of Blood Medicine 2012, 3:51-76

Published Date: 3 August 2012

Targeted dual-color silica nanoparticles provide univocal identification of micrometastases in preclinical models of colorectal cancer

Soster M, Juris R, Bonacchi S, Genovese D, Montalti M, Rampazzo E, Zaccheroni N, Garagnani P, Bussolino F, Prodi L, Marchiò S

International Journal of Nanomedicine 2012, 7:4797-4807

Published Date: 5 September 2012